دورية أكاديمية
Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
| العنوان: | Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines. |
|---|---|
| عنوان ترانسليتريتد: | Posicionamiento en guías nacionales e internacionales de los inhibidores del cotransportador sodio-glucosa tipo 2. |
| المؤلفون: | Morillas C; Servicio de Endocrinología, Unidad de Referencia de Diabetes, Profesor Asociado de Medicina, Hospital Universitario Dr. Peset, Valencia, España Unidad de Endocrinología, IVI-Valencia, Valencia, España. Electronic address: carlos.morinas@uv.es. |
| المصدر: | Medicina clinica [Med Clin (Barc)] 2016 Nov; Vol. 147 Suppl 1, pp. 49-53. |
| نوع المنشور: | Journal Article |
| اللغة: | English; Spanish; Castilian |
| بيانات الدورية: | Publisher: Elsevier España Country of Publication: Spain NLM ID: 0376377 Publication Model: Print Cited Medium: Internet ISSN: 1578-8989 (Electronic) Linking ISSN: 00257753 NLM ISO Abbreviation: Med Clin (Barc) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2009- > : Madrid : Elsevier España Original Publication: Barcelona : Ediciones Doyma, S.A. |
| مواضيع طبية MeSH: | Sodium-Glucose Transporter 2 Inhibitors*, Diabetes Mellitus, Type 2/*drug therapy , Hypoglycemic Agents/*therapeutic use, Benzhydryl Compounds ; Glucose ; Glucosides ; Humans ; Hypoglycemic Agents/pharmacology ; Sodium ; Sodium-Glucose Transporter 2 |
| مستخلص: | Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) selectively and reversibly inhibit sodium-glucose cotransporter-2 (SGLT2), promoting renal glucose excretion and reducing plasma glycaemia. By increasing renal glucose excretion, these drugs favour a negative energy balance, leading to weight loss. Their glucoselowering effect is independent of insulin. Although these drugs have only recently been developed, they have been included in all the main national and international guidelines since 2014. The present review summarises the most important recommendations on the use of SGLT2 in patients with DM2 contained in the most recently published guidelines and consensus statements. (Copyright © 2016 Elsevier España, S.L.U. All rights reserved.) |
| فهرسة مساهمة: | Keywords: American College of Endocrinology and American Association of Clinical Endocrinologists (ACE/AACE); American College of Endocrinology y American Association of Clinical Endocrinologists (ACE/ AACE).; American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD); American Diabetes Association y European Association for the Study of Diabetes (ADA-EASD); Atención Primaria de la Salud (redGDPS); Canagliflozin; Canagliflozina; Clinical practice guidelines (CPG); Cotransportador sodio-glucosa tipo 2 (SGLT2); Dapagliflozin; Dapagliflozina; Diabetes mellitus tipo 2 (DM2); Empagliflozin; Empagliflozina; Guías de práctica clínica; Inhibidores del SGLT2 (iSGLT2); Network of Working Groups for the Study of Diabetes in Primary Health Care (redGDPS); Red de Grupos de Estudio de la Diabetes en; SGLT2 inhibitors (SGLT2-i); Sodium-glucose cotransporter 2 (SGLT2); Type 2 diabetes mellitus (DM2) |
| المشرفين على المادة: | 0 (Benzhydryl Compounds) 0 (Glucosides) 0 (Hypoglycemic Agents) 0 (SLC5A2 protein, human) 0 (Sodium-Glucose Transporter 2) 0 (Sodium-Glucose Transporter 2 Inhibitors) 9NEZ333N27 (Sodium) IY9XDZ35W2 (Glucose) |
| تواريخ الأحداث: | Date Created: 20170802 Date Completed: 20180410 Latest Revision: 20191210 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/S0025-7753(17)30626-7 |
| PMID: | 28760226 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1578-8989 |
|---|---|
| DOI: | 10.1016/S0025-7753(17)30626-7 |